Exxel Pharma to Participate in a 'New to Virtual Investor' Segment
Live moderated video webcast on Wednesday, February 5th at 4:00 PM ET
AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced that it will participate in a "New to Virtual Investor" segment on Wednesday, February 5, 2025 at 4:00 PM ET.
As part of the event, Soren Mogelsvang, PhD, President and Chief Executive Officer of Exxel Pharma, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Investors page of the Company's website (exxelpharma.com). Viewers can also access the event on the Virtual Investor website at virtualinvestorco.com.
About Exxel Pharma
Exxel Pharma is a privately held pharmaceutical company focused on developing innovative therapeutics for neuronal hypersensitivity disorders. The Company's lead program, EX937, is a first-in-class, orally administered, proprietary small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies, EX937 demonstrated robust efficacy in modulating chronic cough across multiple models. Furthermore, it has shown a favorable safety profile and is designed to avoid central side effects by being entirely excluded from the brain. EX937 also holds promise for a range of high-value indications, including hyperactive bladder, peripheral painful neuropathies, and migraine headaches. In addition to EX937, Exxel Pharma is advancing its ARN compounds, a second lead program targeting social anxiety disorder and autism spectrum disorder.
Investor ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: exxel@jtcir.com
SOURCE: Exxel Pharma, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL
Certified Method Enhances Global Botanical Quality and Safety LOS ANGELES, June 11, 2025--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL)—a global authority in analytical science—has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-approved approach for detecting aloins—reinforcing safety and quality benchmarks across botanical and dietary supplement industries. Developed by Herbalife scientists and validated by independent laboratories worldwide, this AOAC-certified method is used to test every batch of Herbalife's aloe-based products, ensuring safety, while preserving aloe vera's natural benefits. Aloe vera is a key ingredient in many of Herbalife's top products, which are sold in more than 90 markets. "This AOAC validation is an important milestone for Herbalife and the industry as a whole," said Gary Swanson, SVP of Global Quality at Herbalife and lead author of the study. "We are proud to lead scientific innovation that enhances botanical ingredient safety, benefitting not only Herbalife products and our customers, but also advancing standards across the industry." Herbalife's method was validated through a global multi-laboratory study involving eight independent laboratories. Each lab tested the same set of six aloe vera samples, including both raw materials and finished products, using HPLC (High-Performance Liquid Chromatography) to measure aloin A, aloin B, and aloe-emodin. The study ensured the method's accuracy and reliability across various labs and product types, with results confirming that it met all performance criteria, including precision and system suitability. "This multi-laboratory validation study supported approval of an analytical method developed by Herbalife scientists as the AOAC 2016.09 Official Final Action Method," said Dr. Katerina Mastovska, deputy executive director and chief science officer, AOAC INTERNATIONAL. "AOAC official methods undergo rigorous scientific evaluation and are highly credible and globally accepted. As such, this method will help strengthen botanical quality and safety standards worldwide." Herbalife has a long-standing commitment to aloe vera research and quality assurance. This dedication has resulted in five patents and three published studies focused on developing safe extraction methods that preserve the plant's natural benefits. While many companies rely solely on supplier certifications to confirm the authenticity of their aloe vera, Herbalife goes further. The company is one of the few in the world using advanced proton nuclear magnetic resonance (NMR) spectrometry—an analytical technique that uses magnetic fields and radio waves to identify the molecular structure of raw materials. This allows Herbalife to independently verify the identity and purity of its aloe vera at the molecular level, ensuring the highest standards of quality, consistency and traceability across its global supply chain. For 45 years, Herbalife has upheld a global commitment to quality through its rigorous Seed to Feed process. This comprehensive system ensures that every ingredient—from responsibly sourced crops cultivated by dedicated farmers to the finished product—meets stringent standards for identity, potency, safety, and purity. Herbalife performs internal testing in ISO 17025-accredited laboratories, verifying that ingredients comply with both company standards and government regulations. The company's science-backed approach, grounded in Good Manufacturing Practices (GMPs) and NSF International standards, delivers consistent, transparent products in more than 90 markets. Supported by a global team of scientists and quality experts, this process strengthens consumer trust and continues to advance industry standards worldwide. Herbalife's aloe vera testing method has been published in Journal of AOAC INTERNATIONAL (Volume 108, Issue 3, Pages 449-471). About Herbalife Ltd. Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit View source version on Contacts Media Contact: media@
Yahoo
16 minutes ago
- Yahoo
Zocks and eMoney Launch AI-Powered Integration to Eliminate Manual Data Entry and Maintenance in Financial Planning
Advisors can now automate fact-finding, follow-ups, and plan updates with bi-directional data sync between Zocks and eMoney SAN FRANCISCO, June 11, 2025--(BUSINESS WIRE)--Zocks, an innovative, privacy-first AI platform that turns client conversations into actionable data and insights, today announced a direct integration with eMoney Advisor (eMoney), a leading provider of technology solutions and services that help people talk about money. This marks the first AI-powered, bi-directional integration between a client intelligence platform and eMoney's financial planning solutions, aimed squarely at eliminating manual data entry and accelerating the planning process for financial advisors. "The planning process can often be delayed, while advisors gather and reconcile information and notes from conversations," said Mark Gilbert, CEO of Zocks. "Reducing that effort, automating data entry and accelerating 'time to advice' is critical in keeping momentum with clients." Zocks automatically creates and maintains structured data from conversations, emails and CRM records for contacts. The integration's bi-directional data sharing enables Zocks to use that information to populate and update 'Facts' data in eMoney, eliminating manual data entry. In return, relevant facts and plan data from eMoney can be utilized by Zocks' AI Agents to support smarter meeting preparation and email responses. "We're excited to offer this integration with Zocks as it furthers our goal at eMoney to streamline and strengthen the financial planning process," said Luke White, Manager, Group Product Management, eMoney. "By reducing time spent on data entry, advisors can spend more time focusing on building meaningful client relationships and delivering high-quality financial plans." The integration, which is available now for joint clients of eMoney and Zocks, builds on Zocks' broader vision of streamlining end-to-end advisor workflows by connecting AI-powered insights with the tools advisors already use every day. "Having led sales at eMoney for many years, I had a front-row seat to the friction in the financial planning process that has long slowed advisors down," said Drew DiMarino, Chief Revenue Officer at Zocks. "This integration directly addresses those pain points. By syncing structured data into and out of eMoney, we're removing the burden of manual entry and giving advisors more time to engage meaningfully with clients, whether that's uncovering new planning needs, preparing for complex reviews, or simply staying ahead of key life changes." To learn more about this integration, Zocks will be hosting a webinar, How Advisors Are Automating Planning in Real Time, on Wednesday, June 18, 2025, at 3 pm ET. For more information about Zocks and the eMoney integration, visit About Zocks Zocks is the AI assistant for financial advisors. The company's platform saves advisors 10 hours a week by automating their meeting notes, intake forms, client emails & more. This enterprise-ready solution transforms client conversations into structured, actionable intelligence for firms of any size. To learn more and start a free trial, visit About eMoney Advisor, LLC eMoney Advisor, LLC ("eMoney") provides technology solutions and services that help people talk about money. Rooted in holistic financial planning, eMoney solutions strengthen client relationships, streamline business operations, enhance business development, and drive overall growth. More than 109,000 financial professionals across firms of all sizes use the eMoney platform to serve more than 6 million households throughout the U.S. For more information, please visit: View source version on Contacts Media Contact: Gregory FCAzocks@
Yahoo
18 minutes ago
- Yahoo
With Rick Perry's backing and $50 million from the state, Texas set to become a leader in psychedelics research
As Texas sets to crack down on the recreational use of cannabis, state leaders are opting to invest $50 million in another plant with purported medicinal benefits – a psychedelic called ibogaine. For several years, people have silently traveled to clinics in Mexico to take ibogaine. The extract of an ancient African shrub has been used across the Texas border to alleviate addiction and brain trauma. Texas Gov. Greg Abbott is set to sign Senate Bill 2308 on Wednesday, creating a consortium of universities, hospitals, and drug developers to conduct clinical trials on an ibogaine drug, with the hopes of receiving U.S. Food and Drug Administration approval. Lawmakers approved $50 million in taxpayer dollars to support this effort, making Texas the global leader in psychedelic research investment. Since Texas is trying to be the first to develop the drug, the legislation ensures Texas retains control of the research and development process. The goal of this investment is to ensure Texans reap the economic benefits from an ibogaine treatment program, not a pharmaceutical company. The investment entitles Texas to at least 20% of any successful ibogaine drug resulting from the trials, with a quarter of that revenue allocated to a fund for state veterans. After a failed attempt in Kentucky to start a state-funded ibogaine drug, Texas has picked up the effort under the leadership of a familiar statewide figure-turned psychedelics cheerleader — former Gov. Rick Perry. 'None of this is possible without Perry,' said Bryan Hubbard, the former chair of the Kentucky Opioid Abatement Advisory Commission and current executive director of the American Ibogaine Initiative. 'He made it happen in Texas. That is a big deal and catches the attention of the nation.' Ibogaine is an illegal drug that has found itself in a unique position where Republicans champion it. This comes as some of them, led by Lt. Gov. Dan Patrick, have made it a mission this session to ban recreational use of THC, which awaits Abbott's approval. Katharine Neill Harris, a drug policy fellow at Rice University's Baker Institute for Public Policy, said it's easy for Republicans to sign on to ibogaine because the intent of it is to medicinally treat addiction. 'Also, this bill doesn't grant public access to ibogaine, and there's nothing in the bill that could really be construed as soft on drugs,' she said. For that reason seemingly, Patrick has publicly thrown his support toward ibogaine as he fends off critics from the left and right for his hardline views on THC. Patrick did not respond to a request for a comment for this story. Harris said Texas' investment in ibogaine could kickstart a trend across states to invest in drug research to address addiction, as private funds have become inconsistent. 'In 2024, the FDA rejected a proposal to approve MDMA-assisted therapy for PTSD. MDMA-assisted therapy for PTSD is one of the more studied alternative psychedelic treatment protocols, and the FDA rejection was a huge blow to private industry, likely leading some to rethink investment in this area,' she said. It was early 2022, and the only thing former Army Ranger Chase Rowan could think about was killing himself. Sixteen years prior, his parachute failed to fully deploy during a nighttime training exercise as his body careened toward the ground at 60 miles per hour. To cope through the pain from the severe brain injury that resulted, the Lubbock resident turned to opioids which morphed into a fentanyl addiction that eventually dissolved his family. 'I was stuck alone. I had no money and no vehicle, just white knuckling sobriety,' Rowan said. When Rowan got to Mexico to test out a novel drug called ibogaine in August of 2022, he wasn't scared, but determined to heal. Upon taking the ibogaine pill, Rowan started seeing images — one of a devil with wings and another of roads leading to childhood memories. The psychedelic journey on his first night opened his eyes to past trauma and the pain he caused to those around him, like a movie. He woke up the next day feeling the happiest he had been in 20 years. 'It felt like a weight was lifted off of me,' he said. 'I got that stuff out of me.' What Rowan was dealing with is a particular high that comes from ibogaine that is often referred to as a 'spiritual awakening' or a greater sense of self. Stanford Medicine conducted a study in 2024 that found 'ibogaine, when combined with magnesium to protect the heart, safely and effectively reduces PTSD, anxiety and depression and improves functioning in veterans with' traumatic brain injury. Hubbard sees no threat of ibogaine becoming recreationally used or abused since it does not provide an enjoyable high and leaves the user in a state of temporary paralysis. Because of this, most never go back for another dose. 'There is no street economy for this drug,' Hubbard said. Ibogaine also comes with potential dangers. Harris calls it one of the 'more complicated psychedelics to administer' because it brings risks of cardiac issues and sudden death. The risks make it more expensive to study and to provide as a treatment, drawing out the years that ibogaine becomes more widely available, Harris said. 'If the FDA were to approve ibogaine for opioid use disorders or other disorders…the treatment could be quite costly,' Harris said. Since leaving his two-year stint as U.S. Energy Secretary during the first Trump administration, Perry has thrown the weight of his reputation behind psychedelics, becoming one of the most high-profile advocates of its research nationally. But the journey to this point started when he still occupied the Governor's Mansion in Austin. 'It's the question I hear the most,' Perry said with a laugh. 'What is a right-wing anti-drug governor doing associated with psychedelics?' In 2006, Perry became close with Navy SEAL veteran Marcus Luttrell who struggled from a brain injury, PTSD and addiction, without access to effective treatments. He recalls Luttrell sleeping with the TV and lights on, trying to comfort his battered mind. When Luttrell told him he was planning to go to Mexico with several other veterans to try ibogaine, Perry was skeptical. 'I remember the first time he told me, and I looked at him the same way a dog does when they hear a funny noise. I remember telling him to be careful with that because I still had my beliefs on drugs at the time, but at the same time, people that I trusted were going to Mexico for this, I had to listen,' Perry said. The data was indisputable to Perry. He unequivocally believes ibogaine takes away addiction and he is ready to tell anyone who will ask him about it. He has since gone on to the Joe Rogan podcast to wax poetic about the drug and other psychedelic treatments. He is a scheduled speaker for a psychedelic conference in Denver. He is also planning to reach out to officials in Israel and Ukraine to initiate ibogaine treatment programs there. 'I have always been open to new knowledge. The same thing with criminal justice reform and in-state tuition, as a Republican, I have my beliefs, but I am willing to change them once looking at the data and science,' Perry said. Hubbard cautioned that ibogaine is not a drug to be taken without medical supervision and Texas is probably at least six years away from seeing any movement on FDA approval for clinical trials. However, he is hopeful that the drug qualifies for a Breakthrough Therapy designation, a pathway that accelerates the regulatory review of drugs showing early promise in treating severe conditions. As of June 30, 2024, the FDA has only granted 587 designations out of the 1,516 requested since 2012. Hubbard believes the current presidential administration will see the momentum in Texas and help expedite the process with the FDA. 'If Texas can create a treatment plan for ibogaine, it might be the most significant achievement in modern medicine for nearly a century,' said Hubbard. Disclosure: Rice University and Rice University's Baker Institute for Public Policy have been financial supporters of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here. Big news: 20 more speakers join the TribFest lineup! New additions include Margaret Spellings, former U.S. secretary of education and CEO of the Bipartisan Policy Center; Michael Curry, former presiding bishop and primate of The Episcopal Church; Beto O'Rourke, former U.S. Representative, D-El Paso; Joe Lonsdale, entrepreneur, founder and managing partner at 8VC; and Katie Phang, journalist and trial lawyer. Get tickets. TribFest 2025 is presented by JPMorganChase.
